Lilly strikes again, buying CAR-T firm Orna for $2.4bn In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

#EliLilly has signed its second pipeline-building deal in two days, reaching an #agreement to buy #invivo #CART developer #OrnaTherapeutics for up to $2.4 billion.